

## Prior authorization requirements for high-level, definitive drug testing

Effective December 1, 2018, prior authorization (PA) requirements will change for high-level, definitive drug testing(s). The high-level, definitive drug testing(s) will require PA for Amerigroup Community Care members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- G0482 — Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, gas chromatography/mass spectrometry (GC/MS) (any type, single or tandem) and liquid chromatography/mass spectrometry (LC/MS) (any type, single or tandem and excluding immunoassays; e.g., immunoassays [IA]; enzyme immunoassay [EIA]; enzyme-linked immunosorbent assay [ELISA]; enzyme multiplied immunoassay technique [EMIT]; fluorescence polarization immunoassay [FPIA]; and enzymatic methods [e.g., alcohol dehydrogenase]); (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength); and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es) including metabolite(s) if performed.
- G0483 — Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays; e.g., IA; EIA; ELISA; EMIT; FPIA; and enzymatic methods [e.g., alcohol dehydrogenase]); (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength); and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es) including metabolite(s) if performed.

<https://providers.amerigroup.com>

To request PA, you may use one of the following methods:

- Availity Portal: <https://www.availity.com>
- Fax:
  - 1-800-964-3627 (Medicaid)
  - 1-844-765-5160 (D-SNP)
- Phone:
  - 1-800-454-3730 (Medicaid)
  - 1-844-799-4129 (D-SNP)

Not all PA requirements are listed here. PA requirements are available on the provider website at <https://providers.amerigroup.com/NJ>. Under *Provider Resources & Documents*, select **Quick Tools**, then **Precertification Lookup Tool**. Contracted and noncontracted providers may call Provider Services for assistance with PA requirements at:

- 1-800-454-3730 (Medicaid)
- 1-844-799-4129 (D-SNP)